The clinical developement of ATL1103 is progressing aggressivly through the current clinical human trials and i would expect from this base we should see ATL1103 focused on commercial production to market.This would sent the value of ANP stock soaring, As you mentioned ANP have previously reported that ATL1103 injection suppressed circulating levels of IGF-I in primates and that toxicology studies have been completed with complete success hence the human trials now at Austin Hospital. Robbbssstttarrrr
ANP Price at posting:
7.0¢ Sentiment: LT Buy Disclosure: Held
